Blog

3 takeaways from the FDA oligo guidance you need to know

In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance . This…

CertaraSeptember 23, 2022

On-Demand Webinar

Pinnacle 21 Data Exchange: Transforming External Vendor Data Management

The volume and complexity of clinical data are growing at a faster pace than the…

CertaraSeptember 19, 2022

Fact Sheet

Accelerating Pediatric Drug Development with Biosimulation and Regulatory Science

CertaraSeptember 13, 2022

Press Coverage

Certara Hosts Seminar on Drug Discovery Challenges in Japan and How Modeling and Simulation Can Solve Them

“Quantitative decision-making with data rather than empirical thinking" - Certara's Modeling & Simulation technology contributes…

CertaraSeptember 13, 2022

Publication

Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach

Discover how species differences in PK and metabolite ratios explain efficacy variation using Phoenix WinNonlin.

CertaraSeptember 11, 2022

Publication

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

See how early clearance drop predicts better response and survival; PopPK built using Phoenix NLME.

CertaraSeptember 6, 2022

On-Demand Webinar

Navigating the Biotech Funding Crunch: How to Achieve Your Next Value Inflection

For the past two years, the biotech sector saw a surge of venture funding and…

CertaraAugust 30, 2022

Publication

Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients

Learn how creatinine clearance and ALT drive PK; simulations show need for adjusted dosing using…

CertaraAugust 29, 2022

Blog

3 major implications of new European clinical trial regulations

Have you heard the buzz around the new European Union Clinical Trial Regulations (EU-CTR) for…

CertaraAugust 25, 2022

Blog

Mind-blowing applications of QSP in drug development: Part 2

Part 2 of this blog series dives further into the June 2022 podcast with R&D…

CertaraAugust 15, 2022

3 takeaways from the FDA oligo guidance you need to know

Pinnacle 21 Data Exchange: Transforming External Vendor Data Management

Accelerating Pediatric Drug Development with Biosimulation and Regulatory Science

Certara Hosts Seminar on Drug Discovery Challenges in Japan and How Modeling and Simulation Can Solve Them

Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Navigating the Biotech Funding Crunch: How to Achieve Your Next Value Inflection

Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients

3 major implications of new European clinical trial regulations

Mind-blowing applications of QSP in drug development: Part 2

Newsletter sign up

Quick links

Solutions

Contact